Alphatec (NASDAQ:ATEC) General Counsel Sells $1,109,549.15 in Stock

Key Points

• General Counsel sale: On March 5, Alphatec GC Tyson Eliot Marshall sold 88,835 shares at an average of $12.49 for a total of $1,109,549.15, reducing his ownership by 13.7% to 559,459 shares (valued ~ $6.99M).
• Company performance and sentiment: Alphatec beat Q4 EPS estimates ($0.06 vs. $0.04) with revenue of $212.93M (up 20.4% YoY); the stock trades around $12.87, has a $1.95B market cap and a consensus analyst rating of "Moderate Buy" with an average target of $22.82.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) General Counsel Tyson Eliot Marshall sold 88,835 shares of the business's stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $12.49, for a total value of $1,109,549.15. Following the completion of the sale, the general counsel owned 559,459 shares of the company's stock, valued at approximately $6,987,642.91. This trade represents a 13.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Alphatec Stock Performance

Shares of ATEC stock traded up $0.64 during trading hours on Monday, reaching $12.87. 4,573,226 shares of the company's stock were exchanged, compared to its average volume of 3,342,702. The company has a quick ratio of 1.28, a current ratio of 2.06 and a debt-to-equity ratio of 40.35. Alphatec Holdings, Inc. has a fifty-two week low of $8.81 and a fifty-two week high of $23.29. The business has a fifty day moving average price of $15.94 and a 200-day moving average price of $17.01. The stock has a market capitalization of $1.95 billion, a P/E ratio of -13.55 and a beta of 1.02.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.02. The business had revenue of $212.93 million for the quarter, compared to analyst estimates of $212.67 million. During the same quarter in the prior year, the firm earned ($0.23) EPS. The firm's quarterly revenue was up 20.4% on a year-over-year basis. Analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Alphatec

Several institutional investors have recently modified their holdings of ATEC. Vanguard Group Inc. raised its position in shares of Alphatec by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,883,626 shares of the medical technology company's stock valued at $144,831,000 after acquiring an additional 68,568 shares during the period. American Century Companies Inc. grew its holdings in Alphatec by 2.6% during the third quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company's stock valued at $92,133,000 after purchasing an additional 159,330 shares during the period. Morgan Stanley increased its stake in Alphatec by 22.0% in the fourth quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company's stock valued at $91,333,000 after purchasing an additional 784,191 shares in the last quarter. State Street Corp raised its holdings in Alphatec by 6.4% in the fourth quarter. State Street Corp now owns 2,889,240 shares of the medical technology company's stock worth $60,790,000 after purchasing an additional 174,287 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Alphatec by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 2,828,026 shares of the medical technology company's stock worth $59,511,000 after purchasing an additional 32,465 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $24.00 price target on shares of Alphatec in a research note on Monday, January 12th. Lake Street Capital reissued a "buy" rating on shares of Alphatec in a report on Wednesday, February 25th. Stifel Nicolaus cut their target price on shares of Alphatec from $24.00 to $20.00 and set a "buy" rating on the stock in a research report on Monday. Barclays raised their target price on shares of Alphatec from $23.00 to $27.00 and gave the company an "overweight" rating in a research note on Wednesday, January 7th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price target on shares of Alphatec in a research note on Monday, January 12th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alphatec presently has an average rating of "Moderate Buy" and an average price target of $22.82.

About Alphatec

Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.